A monoclonal antibody W1 blocks mesothelin-mediated tumor progression.

ABSTRACT: Mesothelin (MSLN) represents an attractive and potential biomarker for targeted cancer therapy. Although MSLN has been implicated in mediating tumorigenesis, its precise physiological function remains incompletely elucidated. Moreover, only a limited number of antibodies have been reported to directly inhibit its function in tumor progression. In this study, we confirmed that the N-terminal domain 1 (D1) of MSLN serves as the key region responsible for mediating binding to tumor cells and promoting migration and invasion through the activation of the matrix metalloproteinase-7 (MMP7) pathway. We further identified two monoclonal antibodies, W1 and A12H, which specifically bind to D1 and domain 3 (D3) of MSLN, respectively. W1 effectively inhibits the interaction between D1 and tumor cells,

SUBMITTER: Wang Q 

PROVIDER: S-EPMC12775852 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature